Your browser doesn't support javascript.
loading
The metabolic drug-drug interaction profile of Dabrafenib: in vitro investigations and quantitative extrapolation of the P450-mediated DDI risk.
Lawrence, Sarah K; Nguyen, Dung; Bowen, Chet; Richards-Peterson, Lauren; Skordos, Konstantine W.
Afiliação
  • Lawrence SK; Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, King of Prussia, Pennsylvania.
  • Nguyen D; Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, King of Prussia, Pennsylvania.
  • Bowen C; Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, King of Prussia, Pennsylvania.
  • Richards-Peterson L; Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, King of Prussia, Pennsylvania.
  • Skordos KW; Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, King of Prussia, Pennsylvania kon.skordos@novartis.com.
Drug Metab Dispos ; 42(7): 1180-90, 2014 Jul.
Article em En | MEDLINE | ID: mdl-24748562
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2014 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2014 Tipo de documento: Article